Tumor-derived Jagged1 promotes cancer progression through immune evasion

Citation:

Meng, Jingjing, et al. “Tumor-derived Jagged1 promotes cancer progression through immune evasion”. Cell Rep 38.10 (2022): , 38, 10, 110492. Web.

Date Published:

2022 03 08

ISSN:

2211-1247

Abstract:

Immune checkpoint inhibitor (ICI) therapy is generating remarkable responses in individuals with cancer, but only a small portion of individuals with breast cancer respond well. Here we report that tumor-derived Jagged1 is a key regulator of the tumor immune microenvironment. Jagged1 promotes tumorigenesis in multiple spontaneous mammary tumor models. Through Jagged1-induced Notch activation, tumor cells increase expression and secretion of multiple cytokines to help recruit macrophages into the tumor microenvironment. Educated macrophages crosstalk with tumor-infiltrating T cells to inhibit T cell proliferation and tumoricidal activity. In individuals with triple-negative breast cancer, a high expression level of Jagged1 correlates with increased macrophage infiltration and decreased T cell activity. Co-administration of an ICI PD-1 antibody with a Notch inhibitor significantly inhibits tumor growth in breast cancer models. Our findings establish a distinct signaling cascade by which Jagged1 promotes adaptive immune evasion of tumor cells and provide several possible therapeutic targets.

DOI:

10.1016/j.celrep.2022.110492

Alternate Journal:

Cell Rep